Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- STATISTICS
February 19, 2007
- R&D NEWS IN BRIEF
February 19, 2007
- New Mitsubishi Tanabe to Strengthen Drug Discovery, Global Presence
February 19, 2007
- Merck, Bristol-Myers Submit NDA for Erbitux
February 19, 2007
- Kirin Pharma to Create 500-MR System in 2007
February 19, 2007
- Three Vaccine Makers Apply for Approval of Pre-pandemic Flu Vaccine
February 19, 2007
- Eli Lilly, Shionogi to Codevelop, Comarket Duloxetine in Japan
February 19, 2007
- Japan, EU Reach Agreement on Confidentiality of Drug Information
February 19, 2007
- Chugai: Sales, Profits Impacted by NHI Price Cuts
February 19, 2007
- REGULATORY NEWS IN BRIEF
February 19, 2007
- Companies Gearing Up for Pollinosis Season
February 19, 2007
- Sawai's New 3-Year Plan to Focus on New Formulations, Data Supply
February 19, 2007
- BUSINESS NEWS IN BRIEF
February 19, 2007
- Nihon Chouzai: Profits Hit By GE Drug Promotion Costs
February 19, 2007
- About 17% of Prescriptions Permit GE Substitution: Survey
February 19, 2007
- ON THE MOVE
February 12, 2007
- 1st Gov't-Private Sector Dialogue Held
February 12, 2007
- BUSINESS NEWS IN BRIEF
February 12, 2007
- NEW PRODUCTS
February 12, 2007
- AstraZeneca to Cut 3,000 Jobs Worldwide
February 12, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…